Company: BEP
Filing Date: 2025-11-12
Form Type: 424B5
Source: 0001193125-25-275856
Chunk: 0

Company: Brookfield Renewable Partners L.P.
Filing Date: 2025-11-12
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration File No. 333-277987 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED MARCH 15, 2024 Brookfield Renewable Partners L.P. US$450,000,908 15,050,200 Limited Partnership Units This offering (this “ Offering”) of limited partnership units (the “ LP Units”) of Brookfield Renewable Partners L.P. (the “ Partnership” and collectively with its subsidiary entities and operating entities (“ Brookfield Renewable”) under this prospectus supplement (this “ Prospectus Supplement”) consists of 15,050,200 LP Units (collectively, with the LP Units issuable upon exercise of the Over-Allotment Option (as defined below), the “ Offered LP Units”) at a price of US$29.90 per Offered LP Unit (the “ Offering Price”). The first distribution in which the purchasers of Offered LP Units will be eligible to participate, if they continue to own the Offered LP Units, will be for the distribution expected to be payable on or about December 31, 2025. Concurrent with the closing of this Offering, a subsidiary of Brookfield Corporation (collectively with its subsidiaries (other than Brookfield Renewable) “ Brookfield”) (the “ Brookfield Purchaser”) will, pursuant to an exemption from the Canadian prospectus and U.S. prospectus registration requirements (the “ Concurrent Private Placement”), purchase an aggregate of 6,967,670LP Units at a price of US$28.704 per LP Unit, representing the Offering Price per Offered LP Unit net of underwriting commissions payable by the Partnership. See “Concurrent Private Placement”. The estimated net proceeds to the Partnership from this Offering after deducting the Underwriters’ (as defined below) fee and the expenses of this Offering, will be approximately US$430,738,941 (US$495,539,082 if the Over-Allotment Option is exercised in full), and the proceeds of the Concurrent Private Placement will be approximately US$200,000,000. We intend to use the net proceeds from this Offering, together with the proceeds of the Concurrent Private Placement, to fund the recently completed acquisition of our increased stake in Isagen (as defined below), future investment opportunities, and for general corporate purposes. The LP Units are listed for trading under the symbol “BEP.UN” on the Toronto Stock Exchange (the “ TSX”) and “BEP” on the New York Stock